Finding new antiviral treatments for COVID-19
Discovery of SARS-CoV-2 antivirals using a replicon assay
['FUNDING_R01'] · EMORY UNIVERSITY · NIH-10893018
This study is looking for new medicines to help treat COVID-19 by finding and improving drugs that can fight the virus, using special techniques to see how the virus works in cells.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | EMORY UNIVERSITY (nih funded) |
| Locations | 1 site (ATLANTA, UNITED STATES) |
| Trial ID | NIH-10893018 on ClinicalTrials.gov |
What this research studies
This research focuses on discovering new antiviral medications specifically targeting the SARS-CoV-2 virus, which causes COVID-19. The team utilizes advanced techniques, including high-throughput screening of chemical libraries and the development of specialized cell lines that mimic the virus's behavior. By identifying and optimizing potential antiviral compounds, the research aims to enhance treatment options for COVID-19 patients. The approach includes innovative methods to visualize viral activity within infected cells, providing insights into how the virus operates.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are at risk of severe COVID-19 infection or those who have tested positive for SARS-CoV-2.
Not a fit: Patients who are not infected with SARS-CoV-2 or those who have already received effective antiviral treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective antiviral treatments that significantly reduce the severity and mortality of COVID-19.
How similar studies have performed: Other research efforts targeting SARS-CoV-2 have shown promise in identifying potential antiviral agents, indicating that this approach has a foundation of success.
Where this research is happening
ATLANTA, UNITED STATES
- EMORY UNIVERSITY — ATLANTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SARAFIANOS, STEFAN G — EMORY UNIVERSITY
- Study coordinator: SARAFIANOS, STEFAN G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.